ducovest

EII:F:F-Eisai Co. Ltd (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 35.88

Change

0.00 (0.00)%

Market Cap

USD 10.32B

Volume

175.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Company Website : https://www.eisai.co.jp

Currency: EUR

Country : Germany

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

 USD 73.13B
MRK:F Merck & Company Inc

N/A

 USD 72.76B
H6D0:F Haleon PLC

N/A

 USD 42.81B
H6D:F Haleon PLC

N/A

 USD 42.44B
TKDA:F Takeda Pharmaceutical Company ..

N/A

 USD 41.84B
TEV:F Teva Pharmaceutical Industries..

N/A

 USD 18.06B
3KY:F HANSOH PHARMAC. HD-00001

N/A

 USD 13.31B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

 USD 12.12B
SH0:F Shionogi & Co. Ltd

N/A

 USD 11.31B
NB3:F Neurocrine Biosciences Inc

N/A

 USD 10.87B

ETFs Containing EII:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.43% 33% F 25% F
Dividend Return 179.65% 89% A- 91% A-
Total Return 160.23% 94% A 94% A
Trailing 12 Months  
Capital Gain -33.43% 33% F 19% F
Dividend Return 296.85% 87% B+ 91% A-
Total Return 263.41% 96% N/A 95% A
Trailing 5 Years  
Capital Gain -20.58% 47% F 29% F
Dividend Return 885.35% 90% A- 91% A-
Total Return 864.76% 96% N/A 94% A
Average Annual (5 Year Horizon)  
Capital Gain -6.96% 44% F 28% F
Dividend Return 114.50% 95% A 95% A
Total Return 121.46% 88% B+ 92% A
Risk Return Profile  
Volatility (Standard Deviation) 116.25% 9% A- 8% B-
Risk Adjusted Return 98.50% 97% N/A 96% N/A
Market Capitalization 10.32B 95% A 86% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector